Applying precision medicine to
find a better solution
Preserving future memories
Alzheon is a clinical-stage biopharmaceutical company with a Phase 3 program in Alzheimer’s disease and a discovery platform of small molecules for the treatment of neurodegenerative disorders.
Our pipeline
Anti-aggregation Platform
Two clinical-stage oral programs and a small-molecule discovery library, united by one anti-aggregation mechanism and a decade of research into the biology of Alzheimer’s.
Lead program
Valiltramiprosate ALZ-801 · oral · twice-daily
DiscoveryPhase 1Phase 2Phase 3
Phase 3 in Early AD completed
Clinical
ALZ-507 oral · once-daily
DiscoveryPhase 1Phase 2Phase 3
First subject dosed in Phase 1
Discovery
Undisclosed small-molecule anti-aggregation library
DiscoveryPhase 1Phase 2Phase 3
Research
Valiltramiprosate has been granted Fast Track designation by the FDA for the treatment of Alzheimer’s disease.
Valiltramiprosate/ALZ-801 acts upstream in amyloid cascade
Mechanism of action publications: Gervais (2007), Kocis (2017); Hey (2018), Liang (2019), Tolar (2020), Tolar (2021), Hey (2024), Abushakra (2024), Tolar (2024), Shastri (2025), Muramatsu (2025). * Effects from non-clinical studies
Newsroom
Latest news
Press ReleaseJul 6, 2026
Alzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4…
Read morePress ReleaseApr 14, 2026
Alzheon to Present Evidence of Neurovascular Protection from Trials with Oral Valiltramiprosate in APOE4/4 Alzheimer’s Patients Leading to…
Read morePress ReleaseApr 7, 2026
